Literature DB >> 19783309

Structural determinants of GAD antigenicity.

Yasir Arafat1, Gustavo Fenalti, James C Whisstock, Ian R Mackay, Maria Garcia de la Banda, Merrill J Rowley, Ashley M Buckle.   

Abstract

Our aim was to ascertain structural determinants of autoantigenicity based on the model of the diabetes autoantigen glutamic acid decarboxylase 65 kDa isoform (GAD65) in comparison with that of the non-autoantigenic isoform GAD67. This difference exists despite the two isoforms having the same fold and high sequence identity. Autoantibodies to GAD65 precede the development of type 1 diabetes and are clinical markers of this and certain neural autoimmune diseases. To date, epitope mapping has been based on particular amino acid differences between the two isoforms, and there is no explanation as to why autoantibodies that react with GAD65 only infrequently cross-react with GAD67. To characterize each isoform of the enzyme and gain insights into their contrasting autoantigenic properties, we have used the recently determined crystal structures of GAD65 and GAD67 to compare their structure, hydrophobicity, electrostatics, flexibility and physiochemical properties. The results revealed striking differences which appear almost exclusively at the C-terminal domain of the isoforms. Whereas GAD65 displayed a highly charged and flexible C-terminal domain containing numerous patches of high electrostatic and solvation energies, these characteristics were absent in the GAD67 molecule. Additionally, analysis indicated potential N-terminal and PLP domain binding sites surrounding the C-terminal domain of GAD65, a major region of autoantigenic activity, but not of GAD67. These features agree with good accuracy with published epitope-mapping data. Our analysis suggests that the high flexibility and charge of GAD65 in the C-terminal domain is coupled with the mobility of its catalytic loop, a property that is absolutely required for its enzymatic function. Thus, the structural features that distinguish GAD65 from GAD67 as a B cell autoantigen are related to functional requirements for its enzymatic mechanism. This could well apply to the various other enzyme autoantigens and, if so, these features could be used as the basis of future predictive strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783309     DOI: 10.1016/j.molimm.2009.08.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasis.

Authors:  Itamar Kass; David E Hoke; Mauricio G S Costa; Cyril F Reboul; Benjamin T Porebski; Nathan P Cowieson; Hervé Leh; Eugenia Pennacchietti; Julia McCoey; Oded Kleifeld; Carla Borri Voltattorni; David Langley; Brendan Roome; Ian R Mackay; Daniel Christ; David Perahia; Malcolm Buckle; Alessandro Paiardini; Daniela De Biase; Ashley M Buckle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

2.  An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Authors:  Bindu Jayakrishnan; David E Hoke; Christopher G Langendorf; Ashley M Buckle; Merrill J Rowley
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

3.  Characterisation of peptide microarrays for studying antibody-antigen binding using surface plasmon resonance imagery.

Authors:  Claude Nogues; Hervé Leh; Christopher G Langendorf; Ruby H P Law; Ashley M Buckle; Malcolm Buckle
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

Review 4.  The autoimmunity of primary biliary cirrhosis and the clonal selection theory.

Authors:  Carlo Selmi; Ian R Mackay; M Eric Gershwin
Journal:  Immunol Cell Biol       Date:  2010-10-26       Impact factor: 5.126

5.  Structural Analysis of an Epitope Candidate of Triosephosphate Isomerase in Opisthorchis viverrini.

Authors:  Jonghyeon Son; Sulhee Kim; So Eun Kim; Haemin Lee; Myoung-Ro Lee; Kwang Yeon Hwang
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.